亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

苯拉唑马布 医学 恶化 肺功能 哮喘 生活质量(医疗保健) 内科学 随机对照试验 嗜酸性粒细胞 美波利祖马布 护理部
作者
Tim Harrison,Pascal Chanez,Francesco Menzella,Giorgio Walter Canonica,Renaud Louis,Borja G. Cosío,Njira Lugogo,Arjun Mohan,Annie Burden,Lawrence McDermott,Esther Garcia Gil,James Zangrilli,Wolfgang Pohl,Robert Voves,Maud Deschampheleire,Renaud Louis,Jean‐Benoît Martinot,Rudi Peché,Kenneth R. Chapman,Amarjit Cheema,Delbert R. Dorscheid,J. Mark FitzGerald,Rémi Gagnon,William Patrick Killorn,Ronald Olivenstein,George Philteos,Clare D. Ramsey,Julia Rolf,Brandie Walker,Ole Hilberg,Tina Skjold,Ingrid Louise Titlestad,Auli Hakulinen,Maritta Kilpeläinen,M. Ben Hayoun,Philippe Bonniaud,Arnaud Bourdin,Pascal Chanez,Fréderic de Blay,Gaëtan Deslée,Gilles Devouassoux,A. Didier,Y. Douadi,Stéphanie Fry,Gilles Garcia,Pierre‐Olivier Girodet,Christophe Leroyer,A. Magnan,Guillaume Mahay,C. Nocent,Christophe Pison,Pauline-Marie Roux,Camille Taillé,Juliana-Angelica Tiotiu,Ekkehard Beck,Margret Jandl,Christian Kaehler,Frank F Käßner,Frank Koesters,Juliane Kronsbein,Thomas Schaum,Christian Schulz,Dirk Skowasch,Christian Taube,Tobias Welte,A de Roux,Bianca Beghé,Francesco Blasi,Giorgio Walter Canonica,Giovanna Elisiana Carpagnano,Cristiano Caruso,Angelo Guido Corsico,Elio Constantino,Nunzio Crimi,Piero Maestrelli,Francesco Menzella,Manlio Milanese,Alberto Papi,Girolamo Pelaia,Laura Pini,Pierachille Santus,Eleonora Savi,Nicola Scichilone,Gianenrico Senna,Giuseppe Spadaro,Adriano Vaghi,Steven Gans,Jurgen Hölters,Bas Langeveld,Willem R. Pieters,Gerald Staaks,Ilonka van Veen,Jan Willem van den Berg,Gunnar Einvik,Sverre Lehmann,Ismael Ali García,Carlos Almonacid,Irina Bobolea,Paloma Campo Mozo,Gustavo de Luiz,Christian Domingo,José María Echave-Sustaeta María-Tomé,Juan Luis García‐Rivero,Borja G. Cosío,A. Gómez-Bastero Fernández,Ruperto González‐Pérez,Aythamy Henríquez Santa,Carlos Martínez‐Rivera,Xavier Muñoz,Jacinto Ramos,José Gregorio Soto Campos,Carmen Vidal Pan,Nikolai Stenfors,Alf Tunsäter,Ines Vinge,Rekha Chaudhuri,Timothy Harrison,Adel Mansur,Shuaib Nasser,Monica Nordstrom,Paul Pfeffer,Dinesh Saralaya,Philip Short,Arun Adlakha,Oral Alpan,Francis Averill,Anil Badhwar,Jose Bardelas,B D Baxter,George Bensch,William Berger,Jonathan A. Bernstein,Tracy Bridges,Ryan Brimeyer,William J. Calhoun,Edward J. Campbell,W. Brett Cherry,Geoffrey Chupp,Lee Clore,John R. Cohn,Jeremy Cole,John J. Condemi,James Cury,Benjamin Davis,Samuel DeLeon,Luis DeLaCruz,Joseph D. Diaz,David Erb,Emeka Eziri,Faisal Fakih,Douglas Fiedler,David A. Fost,Stephen B. Fritz,E. González González,Brad Goodman,Peter A. Gottlieb,Gregory Gottschlich,Richard Gower,Rizan Hajal,James B. Harris,Hengameh Heidarian-Raissy,Albrecht Heyder,David A. Hill,Fernando Holguín,Iftikhar Hussain,Jonathan Illowite,Joshua Jacobs,Mikell Jarratt,Harold B. Kaiser,Neil L. Kao,Ravindra Kashyap,David Kaufman,Edward Kent,Kenneth Kim,Ryan Klein,Monica Kraft,Ritsu Kono,Shahrukh Kureishy,Jeffrey Leflein,Mila A. Leong,Huamin Li,Robert Y. Lin,Njira Lugogo,Michael Marcus,Diego Jose Maselli Caceres,Vinay Mehta,Curtis J. Mello,Mark Millard,Aaron P. Milstone,Arjun Mohan,Wendy C. Moore,Mark Moss,N. Mumneh,Thomas D. O’Brien,David Ostransky,Michael Palumbo,Purvi Parikh,Sudhir Parikh,Amit Patel,Guido O. Pérez,W PLESKOW,Bruce M. Prenner,Dileep Puppala,John Ramey,Joan Reibman,Ramón López de los Reyes,Emory Robinette,Ileana Rodicio,Stephen Ryan,Sudhir Sekhsaria,Barry Sigal,Vinay Sikand,Weily Soong,Selwyn Spangenthal,Roy St. John,Gary C. Steven,Vijay Subramaniam,Kaharu Sumino,Eric Sztejman,Ricardo Tan,Tonny Tanus,Charles S. Thompson,C.E. Thornblade,Manuel Villareal,Sally E. Wenzel,Heidi Zafra,Tomasz M. Ziedalski
出处
期刊:The Lancet Respiratory Medicine [Elsevier]
卷期号:9 (3): 260-274 被引量:125
标识
DOI:10.1016/s2213-2600(20)30414-8
摘要

ANDHI was done to assess the efficacy of benralizumab, including onset of effect and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and nasal polyposis symptoms.This phase 3b, randomised, double-blind, parallel-group, placebo-controlled ANDHI study was completed in adults (aged 18-75 years) with severe eosinophilic asthma with at least 2 exacerbations in the previous year, despite high-dose inhaled corticosteroid plus additional controllers, screening blood eosinophil counts of at least 150 cells per μL, and an Asthma Control Questionnaire 6 (ACQ-6) score of 1·5 or more. Patients who met eligibility criteria were randomly assigned (2:1; stratified by previous exacerbation count [two, or three or more], maintenance oral corticosteroid use, and region), using an integrated web-based response system, to receive benralizumab at 30 mg every 8 weeks (first three doses given 4 weeks apart) or matched placebo for 24 weeks. Primary efficacy measure was annualised asthma exacerbation rate, with rate ratio (RR) calculated over the approximate 24-week follow-up. Secondary efficacy measures included change from baseline to end of treatment (week 24) in St George's Respiratory Questionnaire (SGRQ) total score (key secondary endpoint), FEV1, peak expiratory flow (PEF), ACQ-6, Predominant Symptom and Impairment Assessment (PSIA), Clinician Global Impression of Change (CGI-C), Patient Global Impression of Change (PGI-C), and Sino-Nasal Outcome Test-22 (SNOT-22). All efficacy analyses, except for SNOT-22, were summarised and analysed using the full analysis set on an intention-to-treat population (all randomly assigned patients receiving investigational product, regardless of protocol adherence or continued participation in the study). SNOT-22 was summarised for the subgroup of patients with physician-diagnosed nasal polyposis with informed consent. This study is registered with ClinicalTrials.gov, NCT03170271.Between July 7, 2017, and Sept 25, 2019, 656 patients received benralizumab (n=427) or placebo (n=229). Baseline characteristics were consistent with severe eosinophilic asthma. Benralizumab significantly reduced exacerbation risk by 49% compared with placebo (RR estimate 0·51, 95% CI 0·39-0·65; p<0·0001) over the 24-week treatment period and provided clinically meaningful and statistically significant improvement from baseline to week 24 in SGRQ total score versus placebo (least squares mean change from baseline -8·11 (95% CI -11·41 to -4·82; p<0·0001), with similar differences at earlier timepoints. Benralizumab improved FEV1, PEF, ACQ-6, CGI-C, PGI-C, PSIA, and SNOT-22 at week 24 versus placebo, with differences observed early (within weeks 1 to 4). Adverse events were reported for 271 (63%) of 427 patients on benralizumab versus 143 (62%) of 229 patients on placebo. The most commonly reported adverse events for the 427 patients receiving benralizumab (frequency >5%) were nasopharyngitis (30 [7%]), headache (37 [9%]), sinusitis (28 [7%]), bronchitis (22 [5%]), and pyrexia (26 [6%]). Fewer serious adverse events were reported for benralizumab (23 [5%]) versus placebo (25 [11%]), and the only common serious adverse event (experienced by >1% of patients) was worsening of asthma, which was reported for nine (2%) patients in the benralizumab group and nine (4%) patients in the placebo group.Our results extend the efficacy profile of benralizumab for patients with severe eosinophilic asthma, showing early clinical benefits in patient-reported outcomes, HRQOL, lung function, and nasal polyposis symptoms.AstraZeneca.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wanci应助su采纳,获得10
2秒前
zhangqin完成签到,获得积分10
5秒前
Grayball发布了新的文献求助30
7秒前
木九完成签到 ,获得积分10
8秒前
miao完成签到 ,获得积分10
13秒前
烟花应助lewis采纳,获得10
15秒前
仰山雪完成签到 ,获得积分10
15秒前
星辰大海应助lewis采纳,获得10
15秒前
19秒前
spark810应助科研通管家采纳,获得30
19秒前
52秒前
AYY完成签到,获得积分10
1分钟前
科研通AI2S应助橘子汽水采纳,获得10
1分钟前
Flexy发布了新的文献求助10
1分钟前
霸气的亿先完成签到 ,获得积分10
1分钟前
Magali发布了新的文献求助10
1分钟前
JamesPei应助风中的夕阳采纳,获得10
1分钟前
赘婿应助Flexy采纳,获得10
1分钟前
1分钟前
善学以致用应助舒心盼旋采纳,获得10
1分钟前
科目三应助凯文采纳,获得10
1分钟前
冰糖葫芦不加糖完成签到 ,获得积分10
1分钟前
凯文完成签到 ,获得积分20
1分钟前
Chris完成签到 ,获得积分10
1分钟前
1分钟前
2分钟前
2分钟前
舒心盼旋发布了新的文献求助10
2分钟前
2分钟前
大模型应助Man采纳,获得10
2分钟前
大学生完成签到 ,获得积分10
2分钟前
spark810应助科研通管家采纳,获得30
2分钟前
2分钟前
香蕉觅云应助科研通管家采纳,获得10
2分钟前
李健应助科研通管家采纳,获得30
2分钟前
spark810应助科研通管家采纳,获得30
2分钟前
彭于晏应助科研通管家采纳,获得10
2分钟前
在水一方应助懵懂的朋友采纳,获得10
2分钟前
舒心盼旋完成签到,获得积分10
2分钟前
2分钟前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3162280
求助须知:如何正确求助?哪些是违规求助? 2813284
关于积分的说明 7899607
捐赠科研通 2472592
什么是DOI,文献DOI怎么找? 1316476
科研通“疑难数据库(出版商)”最低求助积分说明 631365
版权声明 602142